Evidence map›Paper›PMID 25243627›Full record

Trial reportBone marrow transplantation2014

Twenty-year follow-up of a randomized trial comparing intraosseous and i.v. BM transplantation.

H Hägglund, M Remberger, O Ringden

Abstract readComparative StudyLetterRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Bone Marrow Cell Trafficking Analyzed byClinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

H HägglundHaematology Centre, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
M Remberger1] Division of Therapeutic Immunology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden [2] Centre for Allogeneic Stem Cell Transplantation (CAST), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
O Ringden1] Division of Therapeutic Immunology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden [2] Centre for Allogeneic Stem Cell Transplantation (CAST), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AntibodiesBone Marrow TransplantationFollow-Up StudiesGraft SurvivalGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansIncidenceNeutrophilsProbabilityRecurrenceTransplantation ConditioningTransplantation, HomologousTreatment OutcomeAntibodies

Identifiers

PMID25243627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.